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INTRODUCTION
Hypertension is an established risk factor for adverse car-
diovascular outcomes, including heart failure, myocardial in-
farction, stroke and cardiovascular death (1-5). The incidence
of morbidity and mortality related to myocardial infarction
and coronary heart disease has been increased in Korea. The
prevalence of antecedent hypertension in patients with acute
myocardial infarction (AMI) varies from 31% to 59% (6-8).
Several studies have reported that a history of hypertension
was shown to be associated with an increased rate of adverse
outcomes after AMI such as stroke, heart failure and cardio-
vascular death (9, 10). Although exact mechanisms are not
clear, the increased incidence of AMI or sudden death in hyper-
tensive patients seems to be related to endothelial damage,
atherosclerosis, insulin resistance, left ventricular hypertro-
phy, and ventricular arrhythmias (11). However, long-term
prognostic impact is still controversial. Nevertheless, Korea
Acute Myocardial Infarction Registry (KAMIR) is in search
for better AMI management and preventive care, as well as
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Clinical Effects of Hypertension on the Mortality of Patients with
Acute Myocardial Infarction
The incidence of ischemic heart disease has been increased rapidly in Korea. How-
ever, the clinical effects of antecedent hypertension on acute myocardial infarction
have not been identified. We assessed the relationship between antecedent hyper-
tension and clinical outcomes in 7,784 patients with acute myocardial infarction in
the Korea Acute Myocardial Infarction Registry during one-year follow-up. Diabetes
mellitus, hyperlipidemia, cerebrovascular disease, heart failure, and peripheral artery
disease were more prevalent in hypertensives (n=3,775) than nonhypertensives
(n=4,009). During hospitalization, hypertensive patients suffered from acute renal
failure, shock, and cerebrovascular event more frequently than in nonhypertensives.
During follow-up of one-year, the incidence of major adverse cardiac events was
higher in hypertensives. In multi-variate adjustment, old age, Killip class ≥III, left
ventricular ejection fraction <45%, systolic blood pressure <90 mmHg on admission,
post procedural TIMI flow grade ≤2, female sex, and history of hypertension were
independent predictors for in-hospital mortality. However antecedent hypertension
was not significantly associated with one-year mortality. Hypertension at the time
of acute myocardial infarction is associated with an increased rate of in-hospital mor-
tality.
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investigating the risk factors for mortality in AMI patients. 
The aim of the present study was to evaluate the impact
of hypertension on the in-hospital events as well as one year
clinical outcomes of patients with AMI in the Korean pop-
ulation.
MATERIALS AND METHODS
Korea Acute Myocardial Infarction Registry
The KAMIR is a prospective, multi-center and observation-
al on-line registry designed to examine current epidemiolo-
gy, in-hospital management, and outcome of patients with
AMI in Korea. A total of 50 university hospitals and com-
munity hospitals with facilities for percutaneous coronary
intervention (PCI) and on-site cardiac surgery, were registered
in KAMIR. This study protocol included age, sex, body mass
index, initial symptom, vital sign, Killip class, symptom onset
time, ambulance arrival time, first medical contact time, trans-
fer time from the first hospital to the primary PCI centers,
door to needle time, door to balloon time, risk factors, past
medications, co-morbidities, electrocardiographic locations
of AMI, initial treatment strategy, drugs, coronary angiogra-
phic findings, in-hospital complications, medical therapy in
hospital and 1, 6, 12-month follow-up major adverse cardiac
event (cardiac death, reinfarction, re-PCI, coronary artery by-
pass graft) (12, 13). 
Patients population, definition, follow-up of major adverse
cardiac events (MACE)
A total of 8,568 patients with acute MI were enrolled in
KAMIR from November 2005 to December 2006, and 7,784
patients (5,430 male and 2,354 female, 64.4±12.9 yr) were
evaluated in the present study. 
AMI was diagnosed if typical rise and gradual fall (troponin)
or more rapid rise and fall (creatine kinase-MB) with at least
one of the following criteria were satisfied: 1) ischemic symp-
toms, 2) development of pathologic Q waves on the electro-
cardiographic reading, 3) electrocardiographic changes indica-
tive of ischemia (ST-segment elevation or depression), 4) coro-
nary artery intervention. Acute myocardial infarction was sub-
categorized into ST-segment elevation myocardial infarction
(STEMI) or non-ST-segment myocardial infarction (NSTEMI).
STEMI was manifested by ST-segment elevations or hyperacute
T waves, and then by T wave inversions, often associated with
evolution of pathologic Q waves. Clinically significant ST-
segment elevation is considered to be present if it is greater
than 1 mm (0.1 mV) in at least two contiguous precordial
leads or in at least two adjacent limb leads and is not attri-
butable to non-ischemic causes. NSTEMI was manifested
by ST-segment depressions or T wave inversions without Q
waves with corroborating laboratory evidence of infarction.
Information on antecedent hypertension and other baseline
data were assessed at first visit. Patients who reported a diag-
nosis of hypertension were considered to have hypertension
or antihypertensive medications antecedent to their MI. Blood
pressure was recorded at first visit and patients with a systolic
blood pressure <90 mmHg on admission were considered
to have low blood pressure. The left ventricular ejection frac-
tion (LVEF) was obtained and averaged in apical 4- and 2-
chamber views by modified Simpson’s method.
Initial treatment strategy was composed of reperfusion ther-
apy, including primary PCI, facilitated PCI and thrombolyt-
ics, and conservative treatment in STEMI and early invasive
treatment including early invasive PCI and early conserva-
tive treatment in NSTEMI. Primary PCI was defined as: 1)
PCI that was performed within 12 hr at admission, 2) PCI
that was performed after 12 hr at admission because of con-
tinuing symptom, 3) PCI that was performed within 36 hr
at admission because of cardiogenic shock. Facilitated PCI
refers to a strategy of planned immediate PCI after adminis-
tering drugs to reduce blood vessel obstruction before the pro-
cedure. Early invasive PCI was defined as PCI in NSTEMI
within 48 hr because of continuing symptom. Elective PCI
was defined as scheduled PCI in patients without symptom.
MACE at 6 months and one-year clinical follow-up were
evaluated. MACE was defined as the composite of 1) all cause
death, 2) non-fatal MI, and 3) re-PCI or coronary artery bypass
graft (CABG). All data were recorded on a standardized, elec-
tronic, web page-based case report form (http://www.kamir.
or.kr) (12, 13).
Statistical analysis
The statistical Package for Social Sciences (SPSS) for Win-
dows, version 12.0 (Chicago, IL, U.S.A.) was used for all anal-
yses. Continuous variables were presented as the mean value
±SD; comparisons were conducted by Student’s t-test. Dis-
crete variables were presented as percentages and relative fre-
quencies and comparisons were conducted by chi-square sta-
tistics or Fisher’s exact test as appropriate. Logistic regression
analysis was performed to identify the independent predic-
tors of primary end points. A P value <0.05 was considered
statistically significant.
RESULTS
Baseline clinical and laboratory characteristics of the study
population
In Table 1, 7,784 eligible patients (5,430 male and 2,354
female, 64.4±12.9 yr) were analyzed. Among them, 3,775
patients (48.5%) reported antecedent hypertension. 
The patients with antecedent hypertension were older (66.8
±11.9 yr vs. 62.1±13.4 yr, P<0.001) and more often female
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(38.4%±22.6%, P<0.001) than the normotensive patients. 
On admission, systolic and diastolic blood pressures were
higher in the patients with antecedent hypertension. Diabetes
mellitus, hyperlipidemia, heart failure, cerebrovascular dis-
ease, peripheral artery disease, previous MI, previous angina,
previous PCI and previous CABG were more significantly
common in hypertensives, compared with in normotensives.
On admission, the hypertensive patients more frequently pre-
sented with non ST-segment elevations on the electrocardio-
gram (44.7% vs. 36.6%, P<0.001). 
The level of serum creatinine, glucose, triglyceride, N-ter-
minal pro-brain natriuretic peptide (NT-proBNP) were high-
er in hypertensives than in nonhypertensives, but the level of
maximum creatine kinase-MB and low density lipoprotein-
cholesterol were lower.
Initial treatment strategy of STEMI and NSTEMI
There were no differences in initial treatment strategy of
STEMI between the two groups (Table 2). However, hyper-
tensives received more frequently conservative treatments in
NSTEMI (45.0% vs. 38.1%, P<0.001).
Coronary angiographic findings and procedural 
characteristics
Left anterior descending artery (LAD) was the most com-
mon infarct related artery (IRA) in both two groups. LAD
was the less common IRA in hypertensives than in nonhy-
pertensives (47.0% vs. 50.6%, P=0.006). Multivessel disease
was more common in hypertensives (63.6% vs. 48.4%, P<
0.001). Lesion type B2 or C according to the American Col-
lege of Cardiology/American Heart Association (ACC/AHA)
classification was more common in hypertensives (79.2% vs.
77.0%, P=0.039). Thrombolysis In Myocardial Infarction
(TIMI) 0-1 flow was present in 53.7% in hypertensives and
55.4% in nonhypertensives (P=0.186).
There was no difference in TIMI flow grade 3 after proce-
dures in the two groups. Drug eluting stent was used in most
cases in both groups (91.5% vs. 92.2%, P=0.379). The aver-
age diameter of stents was larger in nonhypertensives (3.2±
0.4 mm) than in hypertensives (3.1±0.4 mm) (P<0.001).
The number of implanted stents were significantly higher
in hypertensives compared with nonhypertensives (1.6±
0.9 vs. 1.5±0.8, P<0.001).
In-hospital clinical outcomes and medications at discharge
In Table 3, the hypertensive patients suffered from a high-
er incidence of complications during admission (14.6% vs.
PCI, percutaneous coronary intervention; CABG, coronary artery bypass
graft; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-
STEMI; HDL-C, High density lipoprotein-cholesterol; LDL-C, Low den-
sity lipoprotein-cholesterol; hs-CPR, High sensitivity C-reactive protein;
NT-proBNP, N-terminal pro-brain natriuretic peptide.
Characteristics 
Hypertensives 
(n=3,775)
Nonhypertensives 
(n=4,009)
P
Age (yr) 66.8±11.9 62.1±13.4 <0.001
Male, n (%) 2,326 (61.6) 3,104 (77.4) <0.001
Killip class≥3, n (%) 574 (15.2) 433 (10.8) <0.001
Blood pressure on admission 
Systolic 131.6±30.9 124.3±27.1 <0.001
Diastolic 79.4±17.8 76.5±16.7 <0.001
Past history, n (%)
Diabetes mellitus 1,353 (35.8) 783 (19.5) <0.001
Hyperlipidemia 408 (10.8) 244 (6.1) <0.001
Current smoker 1,221 (32.3) 2,051 (51.2) <0.001
Family history 231 (6.1) 258 (6.4) 0.222
Heart failure 109 (2.9) 47 (1.2) <0.001
Cerebrovascular disease 317 (8.4) 126 (3.1) <0.001
Peripheral artery disease 48 (1.3) 25 (0.6) <0.001
Previous myocardial  193 (5.1) 134 (3.3) <0.001
infarction
Previous angina 175 (4.6) 101 (2.5) <0.001
Previous PCI 157 (4.2) 110 (2.7) <0.001
Previous CABG 23 (0.6) 18 (0.4) <0.001
Final diagnosis, n (%)
STEMI 2,071 (54.9) 2,530 (63.1) <0.001
NSTEMI 1,688 (44.7) 1,467 (36.6) <0.001
Echocardiographic findings
LV ejection fraction (%) 51.4±16.7 51.9±22.0 0.262
Laboratory findings
Creatinine (mg/dL) 1.4±2.3 1.1±1.6 <0.001
Maximum creatine 129.9±248.2 158.5±331.7 <0.001
kinase-MB (U/L)
Troponin I (ng/mL) 42.4±80.0 46.4±89.7 0.074
Troponin T (ng/mL) 18.3±115.9 14.8±97.8 0.376
Glucose (mg/dL) 178.5±87.7 164.4±78.3 <0.001
Total cholesterol 182.6±48.3 183.2±48.2 0.543
(mg/dL)
Triglyceride (mg/dL) 131.1±101.7 125.7±111.4 0.033
HDL-C (mg/dL) 45.6±27.3 46.6±36.3 0.231
LDL-C (mg/dL) 116.5±46.7 119.0±50.0 0.038
hs-CPR (mg/dL) 25.6±112.2 23.7±109.9 0.513
NT-proBNP (pg/mL) 3,967.7±8,101.2  2,224.9±5,434.8 <0.001
Table 1. Baseline clinical and laboratory characteristics
STEMI, ST-segment elevation myocardial infarction; PCI, percutaneous
coronary intervention.
Hypertensives
(n=2,009)
Nonhypertensives
(n=2,431)
P
Initial strategy, n (%) 0.241
Reperfusion therapy 1,587 (79.0) 1,960 (80.6)
Thrombolysis, n (%) 228 (11.3) 322 (13.2)
Primary PCI, n (%) 1,347 (67.0) 1,625 (66.8)
Facilitated PCI, n (%) 12 (0.6) 13 (0.5)
Conservative treatment 416 (21.0) 471 (19.4)
Medical treatment, n (%) 83 (4.1) 82 (3.4)
Elective PCI, n (%) 333 (16.9) 389 (16.0)
Table 2. Initial treatment strategy in STEMI
Hypertension in Myocardial Infarction 803
12.2%, P=0.002), acute renal failure (1.5% vs. 0.5%, P<
0.001), shock (0.7% vs. 0.4%, P=0.046), major bleeding
(0.7% vs. 0.4%, P=0.046) and cerebrovascular disease (0.9%
vs. 0.5%, P=0.033) than the nonhypertensive group. The
incidence of in-hospital death was significantly higher in hy-
pertensives (5.9% vs. 4.0%, P<0.001). 
The hypertensive patients were more frequently prescribed
various medications at the time of discharge from hospital,
including angiotensin receptor blocker (21.9% vs. 14.7%,
P<0.001), beta blocker (71.0% vs. 67.6%, P=0.002), calci-
um channel blocker (15.7% vs. 9.9%, P<0.001) and diuret-
ics (24.8% vs. 20.7%, P<0.001) as compared with the non-
hypertensive patients.
Multi-variate analysis of in-hospital mortality
To find clinical factors that could predict the occurrence
of in-hospital death, we used a logistic regression model in
which in-hospital death was the dependent variable. The fol-
lowing risk factors were entered as independent variables: old
age, female sex, post procedural TIMI flow grade ≤2, sys-
tolic blood pressure <90 mmHg on admission, LVEF <45%,
Killip class ≥III, multivessel disease, antecedent hyperten-
sion, diabetes mellitus, and administration of reperfusion ther-
apy. Results of logistic regression demonstrated that old age,
post procedural TIMI flow grade ≤2, systolic blood pressure
<90 mmHg on admission, LVEF <45%, Killip class ≥III,
multivessel disease and antecedent hypertension were inde-
pendent predictors for in-hospital mortality (Table 4).
Multi-variate analysis for predictors of one-year mortality
The cumulative incidence of MACE at one year was 27.6%
in hypertensives and 22.7% in nonhypertensives (P=0.001).
Cardiac death during one-year occurred in 16.1% in hyper-
tensives and 11.0% in nonhypertensives (P<0.001). How-
ever, the rates of non-cardiac death, myocardial infarction,
re-PCI and CABG were not different between the two groups
during one-month and one-year follow-up. 
To find clinical factors that could predict the occurrence
of one-year mortality, we used a logistic regression model in
which one-year mortality was the dependent variable. The
following risk factors were entered as independent variables:
old age, female sex, post procedural TIMI flow grade ≤2,
LVEF <45%, Killip class ≥III, multivessel disease, antece-
dent hypertension, diabetes mellitus, the use of bare metal
stents, administration of reperfusion therapy and beta block-
ers. Results of logistic regression demonstrated that old age,
Killip class ≥III and multivessel disease were independent
predictors for one-year mortality. However, antecedent hyper-
tension was no longer an independent predictor of one-year
mortality (Table 5).
DISCUSSION
KAMIR study revealed that a history of hypertension inde-
Hypertensives
(n=3,775)
Nonhypertensives
(n=4,009)
P
Complications during 550 (14.6) 488 (12.2) 0.002
admission, n (%)
Acute renal failure, n (%) 56 (1.5) 21 (0.5) <0.001
Shock, n (%) 25 (0.7) 15 (0.4) 0.046
Major bleeding, n (%) 25 (0.7) 15 (0.4) 0.046
Cerebrovascular 35 (0.9) 22 (0.5) 0.033
disease, n (%)
Heart failure, n (%) 37 (1.0) 32 (0.8) 0.153
Atrio-ventricular block, 83 (2.2) 81 (2.0) 0.190
n (%)
Ventricular tachycardia 120 (3.2) 152 (3.8) 0.069
or fibrillation, n (%)
In-hospital death, n (%) 222 (5.9) 159 (4.0) <0.001
Table 3. In-hospital clinical outcomes
TIMI, Thrombolysis In Myocardial Infarction; SBP, systolic blood pres-
sure; LVEF, Left ventricular ejection fraction.
Variables HR (95% CI) P
Old age (≥65 yr) 2.175 (1.597-2.963) <0.001
Low post procedural TIMI 5.416 (3.747-7.828) <0.001
flow grade ≤2
Low SBP <90mmHg on admission 4.037 (2.877-5.665) <0.001
Low LVEF <45% 3.096 (2.192-4.373) <0.001
Killip class ≥III 3.569 (2.702-4.714) 0.015
Multivessel disease 1.850 (1.150-2.975) 0.011
Antecedent hypertension 1.332 (1.018-1.743) 0.036
Female sex 1.288 (0.981-1.691) 0.068
History of diabetes mellitus 1.162 (0.880-1.534) 0.289
Reperfusion therapy 0.920 (0.629-1.346) 0.667
Table 4. Multi-variate analysis for the predictors of in-hospital mor-
tality
LVEF, Left ventricular ejection fraction; TIMI, Thrombolysis In Myocardial
Infarction. 
Variables HR (95% CI) P
Old age (≥65 yr) 4.645 (2.969-7.266) <0.001
Killip class ≥III 2.826 (2.012-3.971) <0.001
Multivessel disease 2.383 (1.550-3.664) <0.001
Beta blockers 0.775 (0.541-1.110) 0.164
Antecedent hypertension 1.259 (0.896-1.771) 0.185
Low LVEF <45% 1.433 (0.838-2.448) 0.188
History of diabetes mellitus 3.246 (0.554-19.006) 0.192
Use of bare metal stent 1.485 (0.716-3.079) 0.288
Post procedural TIMI flow grade ≤2 1.280 (0.690-2.374) 0.433
Female sex 0.919 (0.655-1.289) 0.624
Reperfusion therapy 0.941 (0.603-1.467) 0.788
Table 5. Multi-variate analysis for the predictors of one-year mor-
tality
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pendently contributed to a higher in-hospital mortality in
patients of AMI. However, we did not find significant asso-
ciation between antecedent hypertension and one-year mor-
tality by multivariate analysis. 
Epidemiologic studies of treated and untreated hyperten-
sive patients confirmed that there were gradually increasing
incidence of coronary disease, stroke and cardiovascular mor-
tality as the blood pressure rises above 110/75 mmHg (14).
Similar observations have been made in patients with known
coronary heart disease (CHD) (15). CHD is estimated to be
the leading cause of death in the developing as well as in the
developed world. In particular, several studies have reported
that antecedent hypertension after myocardial infarction is
associated with adverse cardiovascular outcomes such as stro-
ke, heart failure, and cardiovascular death (9, 10, 16). Althou-
gh mortality rates for CHD including AMI have been declin-
ed in several developed countries in the past decades (17, 18),
the incidence of CHD including AMI and mortality rate from
the case fatality have been increased in Korea (19, 20). 
Similar to previous study (21), KAMIR revealed the dif-
ferences in demographic parameters in antecedent hyperten-
sives with AMI compared with normotensives. The hyper-
tensive patients tend to be older, and female. There is also a
greater prevalence of diabetes mellitus, hyperlipidemia, heart
failure, cerebrovascular disease, peripheral artery disease, and
previous coronary heart disease with PCI. 
The hypertensive patients received different pharmacolog-
ical treatment from nonhypertnesives in AMI. In our study,
no differences were observed in the use of aspirin, clopidogrel,
angiotensin converting enzyme inhibitor, nitrate, nicorandil
or statin. However, the hypertensive patients received angio-
tensin receptor blocker, beta blocker and calcium channel bloc-
ker more frequently than the nonhypertensive patients. The
comorbidity associated with arterial hypertension such as
heart failure and angina pectoris may be responsible for the
increased protective prescription of medication in these pati-
ents. PCI, if performed in a timely fashion, is the reperfusion
therapy of choice in patients who have had AMI (22, 23). In
reality, Song et al. (24) have reported that the rate of prima-
ry PCI in Korea was much higher than other countries, and
the KAMIR data confirmed this higher rate. There was no
difference in revascularization rate in both two groups. Low
systolic pressure on admission was an independent predictor
of in-hospital mortality.
Mauri et al. (25) have reported that a history of hyperten-
sion in AMI was associated with an increased risk of hemo-
dynamic complications and an increased incidence of sudden
death. Our results also revealed that old age, low post proce-
dural TIMI flow grade, low systolic blood pressure on admis-
sion, low LVEF, high Killip class, multivessel disease and an-
tecedent hypertension were strongly associated with in-hos-
pital mortality. Hypertension also increased risk of cardiac
death and overall MACE during one-month, and one-year
follow-up after MI. Multi-vessel disease and complex lesion
in coronary angiography also associated with poor outcomes
in hypertensive patients (26). However, in contrast to previ-
ous study (27), our study did not reveal that a history of hyper-
tension independently contributes to a higher mortality dur-
ing one-year of follow-up. The poor outcomes after AMI are
probably attributable not to antecedent hypertension but to
the concomitant existence of other risk factors such as an old
age, high Killip class and multivessel disease. These factors
are known to imply poorer prognosis in myocardial infarc-
tion (28). White et al. (29) reported that clinical outcomes
remained poor in elderly patients with heart failure and/or
impaired left ventricular systolic function after acute myocar-
dial infarction, although most received beta-blockers and all
received an ACE inhibitor and/or an angiotensin receptor
blocker. 
This study has several limitations. First, our study is multi-
center prospective registry, and it was not a randomized, con-
trolled study. Thus, there could have been a selection bias in
enrolled patients. Second, the patients of undetected hyper-
tension with low blood pressure on admission was left out
in the analysis and some people were not followed up for one
year. Therefore, there was a possibility of higher mortality in
patients with AMI. Third, we obtained the results for the
blood test from different laboratories, therefore it was possi-
ble that different laboratories may produce different results
for the same sample of blood. Fourth, a value of blood pres-
sure at follow-up was not recorded in the registry, therefore
the relation between the adequate control of blood pressure
and the prognosis of the patients was not estimated. Fifth,
whether long term and more aggressive treatment of elevat-
ed blood pressure in patients with AMI can reduce adverse
outcomes or not remains unknown (10). 
There are large-scale, nationwide or worldwide AMI reg-
istration programs, such as A National Registry of Myocar-
dial Infarction in the U.S. in 1998, A National Survey of Acute
Myocardial infarction and Ischemia (SAMII) in the U.K. in
2000, The Maximal Individual TherRapy of Acute Myocar-
dial Infarction (MITRA) in Germany in 2002 and the Mon-
itoring of Trends and Determinants in Cardiovascular Dis-
ease (MONICA) projects. The World Health Organization
now suggests efficient AMI management systems beyond
providing detailed information. KAMIR is also expected to
make a contribution to the establishment of better AMI man-
agement and preventive care, as well as investigating the risk
factors for mortality in AMI patients.
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